Lacosamide Glenmark

Lacosamide, the active ingredient in Lacosamide Glenmark, is an anticonvulsant presented as an oral formulation for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug used to control seizure activity in the central nervous system. - Partial‑onset seizures: reduces the frequency and severity of seizures. - Epilepsy (adjunct therapy): provides additional seizure control when other medications are insufficient. - Refractory epilepsy: may be used as part of combination therapy for patients whose seizures are not controlled by first‑line agents.

Lacosamide may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate head pain. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Cardiac conduction abnormalities: changes in heart rhythm such as PR‑interval prolongation. - Suicidal ideation: thoughts of self‑harm that need prompt evaluation. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Arrhythmias: irregular heartbeats that may be life‑threatening. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. - Concomitant antiepileptics: monitor for additive CNS effects and possible dose adjustments. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may markedly reduce lacosamide plasma levels. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): increased risk of cardiac conduction delay. - Other sodium‑channel blockers: potential for enhanced CNS depression.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce contraceptive effectiveness; consider alternative methods. - Valproate or other antiepileptics: may require dose adjustments based on clinical response. - Alcohol: can increase dizziness and sedation; advise limited intake.